Mimi Carter

The vision of INNOVATE PASADENA is to create a vibrant ecosystem of technology and design innovation in the greater Pasadena area that supports sustainable economic growth. Advancing greater Pasadena as a center of technology and design innovation by supporting collaboration across business and education to attract companies, entrepreneurs, innovators and capital to the broader community.

Lynx Biosciences | Reimagining Translational Research with Patient-Centric Models Lynx Biosciences (LynxBio) is reshaping translational and reverse translational research by combining patient-derived cell models, microphysiological systems (MPS), and integrated multi-omic analyses to generate clinically meaningful insights—earlier and without reliance on animal models. Our platform supports high-content functional profiling of antibody and cell-based therapies in complex ex vivo co-cultures. These models preserve the native biology of the tumor and immune microenvironment, enabling more predictive, human-relevant data from the outset. As the field shifts toward more scalable, patient-centric approaches to drug development, LynxBio offers a solution built to meet this moment. We work across oncology and immunology indications to: • Profile therapeutic activity in ex vivo models • Integrate imaging, cytokine analysis, and transcriptomics from the same culture • Identify predictive biomarkers and stratify responders • Uncover resistance mechanisms and guide target refinement Our approach enables the resolution of responder and non-responder profiles, mechanistic biomarkers, and functional signatures from limited clinical material—accelerating the development of novel biologics and cell-engaging therapies. Whether you are advancing bispecific antibodies, cell engagers, or radiotherapeutics, LynxBio offers a plug-in, human-relevant platform to de-risk development, guide patient selection, and inform smarter, earlier decisions. Unlock deeper insight from fewer cells. Partner with LynxBio.

Based in the Genomics Capital of San Diego, ROSALIND is the first-ever genomics discovery and collaboration platform specifically designed for scientists and biologists. With ROSALIND, anyone can explore and interpret multi-omic datasets, without any prior bioinformatics skills. Named in honor of pioneering researcher Rosalind Franklin, who made a major contribution to the discovery of the double-helix structure of DNA with her famous photograph 51, the ROSALIND platform aims to simplify the practice of genomic data interpretation, so that biologists, researchers and drug developers can harness the potential of genomic information while reducing costs and increasing productivity. ROSALIND puts the Scientist (back) into the driver’s seat for the exploration and interpretation of datasets, radically reducing the time from sequencing to insight. Register for Free: https://app.rosalind.bio/login Learn more about Enterprise pricing and capabilities by contacting sales@rosalind.bio Follow us on Twitter (@Rosalind_Bio) and Facebook, or visit us at www.rosalind.bio

Wavemaker Three-Sixty Health is the leading U.S. early-stage (Seed and following on at the Series A) venture capital fund focused 100% on healthcare. Launched in 2018, Wavemaker 360 invested into the most promising healthcare startups in North America, with LPs from every sector of the US healthcare system. We are SEEDING HEALTHCARE'S TOMORROW. We invest in healthcare disruptors and entrepreneurs that see how the industry is transforming itself and want to make a big difference.

The vision of INNOVATE PASADENA is to create a vibrant ecosystem of technology and design innovation in the greater Pasadena area that supports sustainable economic growth. Advancing greater Pasadena as a center of technology and design innovation by supporting collaboration across business and education to attract companies, entrepreneurs, innovators and capital to the broader community.

Lynx Biosciences | Reimagining Translational Research with Patient-Centric Models Lynx Biosciences (LynxBio) is reshaping translational and reverse translational research by combining patient-derived cell models, microphysiological systems (MPS), and integrated multi-omic analyses to generate clinically meaningful insights—earlier and without reliance on animal models. Our platform supports high-content functional profiling of antibody and cell-based therapies in complex ex vivo co-cultures. These models preserve the native biology of the tumor and immune microenvironment, enabling more predictive, human-relevant data from the outset. As the field shifts toward more scalable, patient-centric approaches to drug development, LynxBio offers a solution built to meet this moment. We work across oncology and immunology indications to: • Profile therapeutic activity in ex vivo models • Integrate imaging, cytokine analysis, and transcriptomics from the same culture • Identify predictive biomarkers and stratify responders • Uncover resistance mechanisms and guide target refinement Our approach enables the resolution of responder and non-responder profiles, mechanistic biomarkers, and functional signatures from limited clinical material—accelerating the development of novel biologics and cell-engaging therapies. Whether you are advancing bispecific antibodies, cell engagers, or radiotherapeutics, LynxBio offers a plug-in, human-relevant platform to de-risk development, guide patient selection, and inform smarter, earlier decisions. Unlock deeper insight from fewer cells. Partner with LynxBio.

Helping early stage companies accelerate their growth.